News
May 26, 2009—New Health Sciences Inc.
(NHSi) has won a two-year award of $1.9 million from the National Heart, Lung and
Blood Institute of the National Institutes of Health (NIH) to develop a groundbreaking
blood-storage system.
The project aims to develop the Hemanext Anaerobic Storage Platform, which delivers
higher quality blood for transfusion therapy and extends the shelf life of blood
for transfusion.
Click here to
read the complete press release.
March 2009 – Hemanext Trial Results Published in Transfusion
The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have
been accepted for publication in Transfusion. The article entitled “Anaerobic Storage
of Red Blood Cells in a Novel Additive Solution Improves in vivo recovery” will
appear in the March 2009 issue.
The trial was funded by a Phase I SBIR grant from the National Heart, Lung and Blood
Institute. The trial was performed at the Dartmouth-Hitchcock Medical Center under
the supervision of Dr. James AuBuchon, Dr. Larry Dumont, and Dr. Tatsuro Yoshida.
Click here to
read the complete article.
December 1, 2008 – Hemanext Patent Application 10/377,178 for Microvascular Network
Device Allowed by US Patent and Trademark Office
On December 1, 2008 the NHSi received notification from the USPTO that Hemanext
patent application number 10/377,178 for Microvascular Network Device was allowed
for issuance as a patent.
The Microvascular Network Device is a novel technology that measures the ability
of red blood cells to deform and perfuse the capillary beds to deliver oxygen to
end organs.
With the addition of the Microvascular Network Device patent, NHSi now owns a portfolio
of 7 Hemanext-related patents and 7 HVA-related patents.
October 2008 – Hemanext Trial Results Published in Transfusion
The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have
been accepted for publication in Transfusion. The article entitled “The effects
of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells”
will appear in the October 2008 issue.
The trial was funded by a Phase I SBIR grant from the National Heart, Lung and Blood
Institute. The trial was performed at the Dartmouth-Hitchcock Medical Center under
the supervision of Dr. James AuBuchon, Dr. Larry Dumont, and Dr. Tatsuro Yoshida.
Click here to
read the complete article.
October 2008 – Hemanext trial results to be presented at AABB
The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have
been accepted for presentation at the AABB conference in October 2008 in San Diego,
CA.
The trial was funded by a Phase I SBIR grant from the National Heart, Lung and Blood
Institute. The trial was performed at the Dartmouth-Hitchcock Medical Center under
the supervision of Dr. James AuBuchon, Dr. Larry Dumont, and Dr. Tatsuro Yoshida.
Dr. Yoshida, Director, Research and Development at New Health Sciences will present
the trial results…
Click here to
see the complete presentation.
January 2007 – NHSi and Wake Forest Complete Asymptomatic Reference Trial
New Health Sciences and Wake Forest University have completed collection HVA data
from a 364-subject asymptomatic, demographically-balanced cohort of asymptomatic
subjects. The data was collected under an prospective, IRB-approved protocol under
the supervision of Dr. Charles Tegeler at Wake Forest University. The data from
this trial forms the core of a unique reference data set of asymptomatic subjects
stratified by age, sex and race.
December 2007 – FDA clears NHSi to market HVA
On December 22, 2007, the FDA cleared NHSi’s Hemodymanic Vascular Analysis (HVA)
for commercial sale as an aid in the diagnosis of neurovascular disease.
August 2007 – NHSi awarded $280,000 contract from major pharmaceutical company
New Health Sciences, inc has been awarded a $280,000 contract to utilize its Hemodynamic
Vascular Analysis to measure the cerebral vascular response to a new drug under
development for the treatment of dementia.
June 3, 2007 – NHSi and the Cleveland Clinic Complete Normal Pressure Hydrocephalus
Study
NHSi and the Cleveland Clinic Foundation have completed a prospective, clinical
trial of 30 patients undergoing extended CSF trial lumbar drainage for the diagnosis.
In thirty patients who presented with ventriculomegaly and one or more of the triad
symptoms (gait impairment, cognitive impairment, and urinary incontinence), TCD
measures were obtained from 23 vessel segments and/or ensembles of segments in 16
CSF drainage “responders” and 14 “non-responders” immediately before and after 36-hour,
lumbar CSF drainage procedure for the diagnosis of NPH.
TCD data were analyzed using Hemodynamic Vascular Analysis (HVA) to measure differences
in the HVA/TCD parameters (MFV, PSV, SA, and PI) between “responders” and “non-responsders”
at presentation and percent change in the HVA/TCD parameters with CSF trial drainage.
The HVA data showed significant differences in between responders and non-responders
both at presentation and after CSF removal. HVA showed a unique pattern of specific
vessel sites that was significantly different between responders and non-responders
in combination and individually. HVA was able to classify treatment responders from
non-responders with 81.8% sensitivity and 75% specificity.
January 1, 2006 – HVA in Altitude Sickness Research to be published in Wilderness
and Environmental Medicine.
NHSi’s research elucidating the mechanism underlying altitude sickness has been
accepted for publication in the journal of Wilderness and Environmental Medicine
in an article entitled “Cerebrovascular Dynamics and Vascular Endothelial Growth
Factor in Acute Mountain Sickness”.
Click here to
read the complete article.